Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both groups, weight loss was about 6% lower in men than in women, AP said. Both groups saw health improvements in blood pressure, blood sugar and blood fat levels, too.

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% loss for those who took Wegovy. The tirzepatide group t